Form 4: Alnylam CEO Yvonne Greenstreet Executes Pre-Planned Stock Option Exercises and Sales

Alnylam Pharmaceuticals CEO Yvonne Greenstreet engaged in pre-scheduled transactions, exercising stock options and selling common stock, as part of a Rule 10b5-1(c) trading plan.

Summary

• Yvonne Greenstreet, Chief Executive Officer and Director of Alnylam Pharmaceuticals, Inc. (ALNY), reported transactions involving the company's common stock.
• On May 30, 2025, Ms. Greenstreet acquired 12,081 shares at $119.13 and 19,559 shares at $118.05 through stock option exercises.
• On the same date, she disposed of 25,469 shares at $304 and 6,171 shares at $306.
• On June 2, 2025, she acquired an additional 12,080 shares at $119.13 and 7,217 shares at $118.05 via option exercises.
• Also on June 2, 2025, she sold 19,297 shares at $306.
• All reported transactions were conducted under a Rule 10b5-1(c) trading plan established on September 12, 2024.
• Following these transactions, Ms. Greenstreet directly beneficially owns 48,948 shares of common stock and indirectly owns 407 shares through a managed 401(k) account.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an insider sale can sometimes be viewed negatively, these transactions were pre-planned under a 10b5-1 plan, which mitigates concerns about opportunistic selling. The significant profit realized from option exercises also reflects positively on the company's stock performance.

Positives

• The transactions were executed under a Rule 10b5-1(c) trading plan, indicating pre-planned and not reactive trading.
• The sales were executed at significantly higher prices ($304-$306) than the option exercise prices ($118.05-$119.13), demonstrating profitability for the insider.
• The CEO retains a substantial direct beneficial ownership of 48,948 shares, plus indirect ownership, indicating continued alignment with shareholder interests.

Negatives

• The sale of a significant number of shares by a key executive could be perceived negatively by some investors, even if pre-planned.

Future Outlook

This Form 4 filing details past transactions and does not provide forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 12, 2024.

Industry Context

This filing is a routine insider transaction report and does not provide specific insights into broader industry trends within the biotechnology or pharmaceutical sectors. However, the profitability of the option exercises and sales reflects the company's stock performance, which is generally influenced by industry-specific factors such as drug development, regulatory approvals, and market demand for its products.

Comparison to Industry Standards

• As a Form 4 filing, this document reports individual insider transactions and does not contain information suitable for direct comparison to industry-wide financial benchmarks or specific project results of comparable companies. The profitability of the option exercises and sales is specific to Alnylam's stock performance relative to the option strike prices.

Stakeholder Impact

• Shareholders: The pre-planned nature of the sales under a 10b5-1 plan suggests a routine liquidity event for the CEO rather than a signal of lack of confidence in the company. The CEO retains significant direct and indirect ownership.
• Employees: The mention of the 401(k) matching contribution program indicates standard employee benefits are in place.

Next Steps

• The document does not outline any specific future actions, events, or milestones for the company, as it is a report of completed insider transactions.

Key Dates

Keywords

Alnylam Pharmaceuticals, ALNY, Yvonne Greenstreet, SEC Form 4, Insider Trading, Stock Options, Rule 10b5-1, Beneficial Ownership, Executive Compensation, Biotechnology, Pharmaceuticals